Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05669430 · ClinicalTrials.gov registry record · Phase 1
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
A Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, Adult, sponsored by GV20 Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 365
- Enrollment target
- 13
- Study locations
NCT05669430: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, Adult, sponsored by GV20 Therapeutics.
NCT05669430 is a Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, Adult that is actively recruiting participants, run by GV20 Therapeutics. The registered enrollment target is 365 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (44% lower). The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05669430, a Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, Adult, is actively recruiting participants, sponsored by GV20 Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 365 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Primary Outcome
ORR
Conditions Studied
Interventions
- BIOLOGICAL GV20-0251
- BIOLOGICAL GV20-0251 and Pembrolizumab [KEYTRUDA®]
Study Locations (13)
Texas
- Oncology Consultants, P.A. - Houston
- The University of Texas M. D. Anderson Cancer Center - Houston
California
- The Angeles Clinic and Research Institute - Los Angeles
Colorado
- HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE - Denver
Connecticut
- Yale University - New Haven
Florida
- Florida Cancer Specialists & Research Institute, LLC - Fort Myers
Indiana
- Community Health Network, Inc. - Indianapolis
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2023-03-23 |
| Est. Completion | 2027-09-05 |
| Phase | Phase 1 |
What NCT05669430 shows while recruiting
NCT05669430 is an interventional study that assigns participants to a tested intervention. The registered 365 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (44% lower).
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which GV20-0251 is the first listed.
NCT05669430 lists 13 locations in 12 states (Texas, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT05669430 about?
NCT05669430 is a clinical study titled "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies". This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
What is the current status of trial NCT05669430?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 365 participants. The study started on 2023-03-23. Estimated completion is 2027-09-05.
What conditions does trial NCT05669430 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Solid Tumor, Adult, Cutaneous Melanoma, Refractory Cancer, Endometrial Carcinoma (EC).
What interventions are being tested in trial NCT05669430?
The interventions under investigation include: GV20-0251 (BIOLOGICAL), GV20-0251 and Pembrolizumab [KEYTRUDA®] (BIOLOGICAL).
Who is sponsoring clinical trial NCT05669430?
This trial is sponsored by GV20 Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05669430 being conducted?
This trial has 13 study locations across California, Colorado, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05669430's enrollment target sits among peer trials
365 105th of 454 higher than 350 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05065840 · 365 participants · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
- NCT05303519 · 365 participants · Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NCT05592626 · 365 participants · Phase 1
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI